市場調查報告書

中國的Basiliximab市場分析

Investigation Report on China's Basiliximab Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 907274
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Basiliximab市場分析 Investigation Report on China's Basiliximab Market, 2019-2023
出版日期: 2019年08月20日內容資訊: 英文 30 Pages
簡介

本報告提供中國國內的Basiliximab市場相關分析,產品的概要、功效和授權情形,整體市場規模趨勢預測 (過去、今後5年份),市場價格的變化及預測,主要企業的簡介與市場佔有率等資訊彙整,為您概述為以下內容。

第1章 Basiliximab的相關概念

  • Basiliximab的適應症
  • 中國的Basiliximab市場發展
  • 中國國內的Basiliximab的相關專利和政府核准趨勢
  • 中國的器官移植、腎臟移植的實施數量

第2章 中國國內的Basiliximab的銷售量

  • Basiliximab的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • Basiliximab的銷售量
  • Basiliximab的按銷售額:劑型 (過去5年份)

第3章 Basiliximab的主要製造商分析

  • 主要廠商的市場佔有率分析
    • 以金額為準
    • 以數量為準
  • Novartis
    • 企業簡介
    • 中國國內的Basiliximab的銷售量

第4章 Basiliximab國內價格

  • Novartis (Simulect)
    • 在中國各地的Simulect的零售價格
    • Basiliximab的價格趨勢
  • Basiliximab的價格趨勢

第5章 中國的Basiliximab市場未來展望

  • 對市場的影響要素
    • 推動市場要素與市場機會
    • 威脅與課題
  • 市場規模的預測 (今後5年份)
  • 市場趨勢的預測 (今後5年份)
目錄
Product Code: 1908402

Description

In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia.

According to CRI, the incidence of chronic kidney disease in China stays at a high level in recent years. The reasons are as follows: First, the growing economy, increasing urbanization rate and aging population of China bring about irrational changes such as excessive intake of some nutrients (carbohydrates, fat, salt, etc.) and less exercises. Second, increasing work stress, insufficient sleep, excessive mental stress, smoking, excessive drinking and worsening environmental pollution increase the incidence of diabetes, hypertension and hyperlipidemia and chronic kidney disease that is secondary to such metabolic diseases. Third, infections (hepatitis, etc.), drug-induced renal injuries and increasingly aging population push up the incidence of kidney diseases.

As Chinese people have weak health awareness, most chronic kidney disease patients do not find themselves sick until the disease is serious, which makes it difficult to treat the disease. Once renal failure occurs, expensive treatment will become a heavy burden on a patient's family. In addition, due to insufficient kidneys and high costs, every year, only less than 1% uremic patients in China receive kidney transplant.

By Aug. 2019, 178 hospitals in China have been approved to carry out organ transplantation. Of them, 97 have the qualifications for liver transplantation, 136 have the qualifications for kidney transplantation, 46 have the qualifications for heart transplantation, 32 have the qualifications for lung transplantation and 43 have the qualifications for pancreas transplantation and small intestine transplantation. Overall, the hospitals qualified for organ transplantation are concentrated in economically developed regions such as Beijing, Guangdong, Shanghai and Zhejiang. In 2017, China had 10,793 cases of kidney transplantation, ranking the second in the world. These cases occurred in 28 provincial-level administrative regions. Nine regions performed more than 500 kidney transplants respectively, accounting for 74% of the national total.

In China, the one-year graft survival rate and three-year graft survival rate after kidney transplantation have reached 97.90% and 92.65% respectively. But the rejection from and immunosuppressive therapy for recipients in the late stage of transplantation remain major clinical problems.

In China, Basiliximab is used to prevent early acute rejection of kidney transplant. It is usually used together with the immunosuppressive therapy based on cyclosporine and corticosteroids (for adults and children) or the long-term immunosuppressive therapy based on cyclosporine, corticosteroids and azathioprine or mycophenolate mofetil (for adults only).

The only Basiliximab product approved to be sold in China is Simulect, the brand-name drug by Novartis. Simulect was approved to be sold in the United States in 1998, in the E.U. in Oct. 1998 and in China in 2003.

According to CRI's market survey, the sales value of Basiliximab grew rapidly after the drug entered China. In 2017, it was close to CNY 100 million, representing a CAGR of over 20% from 2013 to 2017.

CRI expects that China's Basiliximab market will maintain a high growth rate from 2019 to 2023. On one hand, domestic enterprises will probably launch generic drugs. On the other hand, Basiliximab will probably have more applications in fields such as liver transplantation.

Topics covered:

  • Incidence of chronic kidney disease in China
  • Organ transplantation and kidney transplantation in China
  • Status of China's Basiliximab market
  • Retail prices of Basiliximab in China
  • Major factors influencing development of China's Basiliximab market from 2019 to 2023
  • Prospect of China's Basiliximab market from 2019 to 2023

Table of Contents

1 Relevant Concepts of Basiliximab

  • 1.1 Indications for Basiliximab
  • 1.2 Development History of Basiliximab in China
  • 1.3 Patents and Government Approval on Basiliximab in China
  • 1.4 Organ Transplantation and Kidney Transplantation in China

2 Sales of Basiliximab in China, 2013-2017

  • 2.1 Sales Value of Basiliximab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.1 Sales Volume of Basiliximab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Basiliximab by Dosage Form in China, 2013-2017
    • 2.3.1 Sales Volume
    • 2.3.2 Sales Value

3 Analysis on Major Basiliximab Manufacturers in China, 2013-2018

  • 3.1 Analysis on Market Share of Major Basiliximab Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Novartis
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Basiliximab by Novartis in China

4 Prices of Basiliximab in China, 2017-2018

  • 4.1 Novartis (Simulect)
    • 4.1.1 Retail Prices of Simulect in Different Parts of China
    • 4.1.2 Price Trend of Basiliximab

5 Prospect of China's Basiliximab Market, 2019-2023

  • 5.1 Factors Influencing Development of China's Basiliximab Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Patents on Basiliximab in China
  • Chart Government Approval on Basiliximab in China
  • Chart Sales of Basiliximab in China, 2013-2017
  • Chart Sales Value of Basiliximab in Parts of China, 2013-2017
  • Chart Sales Volume of Basiliximab in China, 2013-2017
  • Chart Sales Volume of Basiliximab in Parts of China, 2013-2017
  • Chart Sales Value of Basiliximab Injections in China, 2013-2017
  • Chart Sales Value of Basiliximab by Novartis in China, 2013-2017
  • Chart Prices of Basiliximab by Novartis (Simulect) in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Basiliximab in China, 2019-2023
Back to Top